NASDAQ:RMTI - Rockwell Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 489.39 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.51
▲ +0.04 (8.53%)

This chart shows the closing price for RMTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rockwell Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMTI

Analyst Price Target is $3.00
▲ +489.39% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Rockwell Medical in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 489.39% upside from the last price of $0.51.

This chart shows the closing price for RMTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Rockwell Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2022HC WainwrightLower Price TargetBuy$5.00 ➝ $3.00Low
9/7/2021HC WainwrightLower Price TargetBuy$5.50 ➝ $5.00Low
6/29/2021HC WainwrightReiterated RatingBuy$5.50Medium
2/8/2021HC WainwrightLower Price TargetBuy$9.00 ➝ $5.50Medium
7/14/2020HC WainwrightReiterated RatingBuy$9.00High
5/19/2020HC WainwrightReiterated RatingBuy$9.00High
4/21/2020HC WainwrightReiterated RatingBuy$9.00Medium
4/7/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $9.00Low
1/21/2020HC WainwrightReiterated RatingBuy$11.00High
12/2/2019HC WainwrightReiterated RatingBuy$11.00Low
11/11/2019Piper Jaffray CompaniesLower Price TargetReduce ➝ Overweight$10.00 ➝ $6.00High
10/28/2019HC WainwrightReiterated RatingBuy$11.00Low
6/24/2019Cantor FitzgeraldInitiated CoverageOverweight$11.00Medium
6/24/2019Piper Jaffray CompaniesInitiated CoverageOverweight$10.00 ➝ $10.00Medium
6/19/2019Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformHigh
5/28/2019HC WainwrightSet Price TargetBuy$12.00High
5/13/2019HC WainwrightInitiated CoverageBuy ➝ Buy$11.00High
3/18/2019Ifs SecuritiesUpgradeOutperform ➝ Strong-BuyHigh
10/19/2018Ifs SecuritiesReiterated RatingStrong-Buy ➝ Outperform$11.00Medium
8/14/2017Ifs SecuritiesInitiated CoverageStrong-Buy$11.00Medium
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/21/2021
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Rockwell Medical logo
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.
Read More

Today's Range

Now: $0.51
Low: $0.45
High: $0.51

50 Day Range

MA: $0.43
Low: $0.37
High: $0.55

52 Week Range

Now: $0.51
Low: $0.34
High: $1.98

Volume

2,631,689 shs

Average Volume

6,372,591 shs

Market Capitalization

$47.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Rockwell Medical?

The following equities research analysts have issued research reports on Rockwell Medical in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for RMTI.

What is the current price target for Rockwell Medical?

1 Wall Street analysts have set twelve-month price targets for Rockwell Medical in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 538.3%. HC Wainwright has the highest price target set, predicting RMTI will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Rockwell Medical in the next year.
View the latest price targets for RMTI.

What is the current consensus analyst rating for Rockwell Medical?

Rockwell Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RMTI will outperform the market and that investors should add to their positions of Rockwell Medical.
View the latest ratings for RMTI.

What other companies compete with Rockwell Medical?

How do I contact Rockwell Medical's investor relations team?

Rockwell Medical's physical mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The company's listed phone number is (248) 960-9009 and its investor relations email address is [email protected] The official website for Rockwell Medical is www.rockwellmed.com.